Primary Myelofibrosis with MPL S505N Mutation: The First Case Reported in Korea.
- Author:
Ung Jun KIM
1
;
Ho Jong LEE
;
In Sun CHOI
;
Seong Ho KANG
;
Sook Jin JANG
;
Dae Soo MOON
;
Geon PARK
Author Information
- Publication Type:Case Report
- Keywords: Myeloproliferative neoplasm; Primary myelofibrosis; MPL S505N mutation; 13q deletion
- MeSH: Aged; Anemia; Biopsy; Blood Cell Count; Bone Marrow; Clone Cells; Cloning, Organism; Cytogenetics; Diagnosis; Dizziness; Epistaxis; Exons; Fibrosis; Granulocyte Precursor Cells; Hemorrhage; Humans; Korea*; Leukocytosis; Male; Mutation, Missense; Pneumonia; Polymerase Chain Reaction; Primary Myelofibrosis*; Reticulin; Sepsis; T-Lymphocytes; Tears; Thrombocytopenia
- From:Laboratory Medicine Online 2018;8(4):167-170
- CountryRepublic of Korea
- Language:Korean
- Abstract: MPL mutation is an important molecular marker in myeloproliferative neoplasms (MPN). Although MPL W515 is a hot spot for missense mutations in MPN, MPL S505 mutations have been reported in both familial and non-familial MPN. A 72-year-old male visited the hospital, complaining mainly of dizziness and epistaxis. Leukocytosis, anemia, thrombocytopenia, tear drop cells, nucleated RBCs, and myeloblasts were observed in both complete blood cell counts and peripheral blood smears. Bone marrow aspiration failed due to dilution with peripheral blood. BM biopsy indicated hypercellular marrow, megakaryocytic proliferation with atypia, and grade 3 reticulin fibrosis. Conventional cytogenetics results were as follows: 46,XY,del(13)(q12q22)[19]/46,XY[1]. Molecular studies did not detect JAK2 V617F, BCR/ABL translocation, JAK2 exon 12, and CALR exon 9 mutations. The MPL S505N mutation was verified by colony PCR and Sanger sequencing following gene cloning. Based on the above findings, a diagnosis of overt primary myelofibrosis (PMF) was indicated. Mutation studies of buccal and T cells were not conducted. Further, family members were not subjected to mutation studies. Therefore, we were unable to determine whether this mutation was familial or non-familial. Six months after the first visit to the hospital, the patient died due to pneumonia and sepsis. Thrombotic symptoms or major bleeding events did not develop during the survival period following diagnosis of PMF. To the best of our knowledge, this may be the first reported case of PMF with the MPL S505N mutation in Korea.
